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   ABSTRACT 
Animal models 
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   INTRODUCTION 
Types of AOs 
   CONCLUSION 
 What’s the cause of DMD? Which are the current treatments? 
ANIMAL 
SUBTYPE/ 
BREED 
MUTATION 
OTHER 
CHARACTERIST
ICS 
MICE mdx STOP in exon 23 
Myofibers 
without 
dystrophin and 
some revertent 
miofibers 
DOG 
Golden retriever 
Splice site point 
mutation, with 
skipping of exon 
7 in transcript 
Models more 
similar to human 
phenotipe  
German 
shorthaired 
pointer 
Deletion 
encompassing 
the entire 
dystrophin gene 
Cavalier king 
Charles spaniel 
Splice site point 
mutation, with 
skipping of exon 
50 in transcript 
Pembroke Welsh 
corgi 
Insertion in 
intron 13 
Labrador 
retriever 
Insertion in 
intron 19 
Cocker spaniel 
Four nucleotide 
deletion in exon 
65 
Tibetan terrier 
Deletion of exons 
8-29 
Rottweiler 
Nonsense point 
mutation in exon 
58 
TREATMENT EXPLANATION 
Drugs  
Glucocorticoids (prednisone and 
deflazacort) which increase strength and 
muscular function 
Cell therapy 
Introduction of precursor or stem cells 
into the affected tissue where are 
differentiated to normal muscular cells 
Gene therapy 
Introduction of dystrophin gene or 
variants into the affected tissue. A 
type of gene therapy is Exon-Skipping 
Duchenne Muscular Dystrophy (DMD) is a neuromuscular degenerative disease linked to X chromosome caused 
by a mutation in the dystrophin gene. DMD affects 1/3500 males and causes premature death, before their 30s, 
due generally to cardiovascular dysfunctions. Patients have a early onset of the disease, between 2 and 5 years 
old, and at the age of 13 most of them have to use a wheelchair. There are three main treatments for the 
disease but only drugs are being used nowadays. Last investigations in the field propose cell therapy and gene 
therapy as alternatives.  
Mutations in the dystrophin gene (2.5 millions of bp with 79 
exons) cause the truncation of the protein dystrophin which is 
mostly expressed in the muscular tissue and in the brain.  
 
Dystrophin links the citoesqueleton and the extracellular matrix 
maintaining the stability during the contraction. When it is 
interrupted, in patients, there are problems during contraction.  
 
Patients have necrosis of the esqueletic muscular  fibers and 
invasion of inflammatory cells. There is a degeneration of 
muscle which is substituted by fibroadipos tissue.  
The exon-skipping therapy consists on the introduction of antisense oligonucleotides (AOs) at local or systemic level to generate a shorter but functional dystrophin product. The AOs are short sequences (20-25bp) 
complementary to a pre-mRNA region near the acceptor o donor sites of splicing or between exons. As a result the splicing machinery is altered and the final mRNA, which is shorter, generates a truncated protein. This 
truncation doesn’t include the internal region of the protein and the N terminal and C terminal regions, the most important ones, remain functional. 
CAUSE  OF THE 
DISEASE 
TREATMENT 
WITH AO 
There are two main types of chemicals used in clinical 
trials as AOs: 2’-O-methyl phosphorothiate antisense 
oligonucleotides (2’-O-MePS AO), and 
phosphorodiamidate morpholino oligomers (PMO). PMO 
has a stronger pairing to target RNA than RNA or DNA. 
Figure 1. Red highlights the differences in the chemistry from RNA 
or DNA. 
Genotipe and phenotipe are very similar to humans with DMD 
Figure 2. CKCS-MD phenotipe. 
Immunochemestry of untreated 
CKCS-MD skeletal muscle compared 
with control dog muscle 
Figure 3. Genotype of CKCS-MD. (A and B) RT-
PCR of mRNA extracted from skeletal muscle from 
a control dog (2) and a case (3). There is a 
deletion of 109bp. (C) Direct sequencing of 
genomic DNA revealed a G-T missense mutation in 
the 5’ consensus splice cite in intro 50.  
Figure 4.Antisense oligonucleotide mediated skipping of exon 51 restores 
protein expression. (A and B) RT-PCR of mRNA extracted from cultured canine 
myoblasts in absence (line 1) or presence (line 2) of AVI-4658. (C) Western 
immunoblot of protein extracts from treated (+) and untreated (-) CKCS-MD 
myoblasts demonstrate the re-expression of dystrophin following exon 51 skipping in 
treated cells. 
TREATMENT WITH AVI-4658 (PMO 
COMPLEMENTARY TO EXON 51) 
This phase 2, dose-escalation study was performed with 19 patients 
between 5 and 15 years old with an out-of frame deletion eligible for 
correction by skipping of exon 51. These patients were treated with 
intravenous infusion of different doses of AVI-4658.  
Figure 5. 
Dystrophin 
protein 
expression in 
the seven 
patients who 
responded to 
treatment. (A) 
Transverse 
sections of post 
and pre treated 
muscle 
specimens 
immunolabelled. 
(B) Post-
treatment biopsy 
samples from 
patients P15 and 
P18. (C) Western 
blotting of pre 
and post-
treatment muscle 
biopsy samples. 
Figure 6. Post-treated biopsies. 
The expression of α-sarcoglican and 
neuronal nitric oxid synthase (NOS) in 
post-treated patients 18 and 19 is 
also restored in the sacolemma.    
 
Figure 7. Inflammatory infiltrates quantification on pretreatment and 
post-treatment muscle samples. Muscle sections were incubated with 
antibodies againts CD3, CD4 and CD8 
The gene therapy of Duchenne Muscular Dystrophy has always had two main difficulties: the length of the gene and to target all the affected tissues by systemic administration. The exon-skipping seems to solve this two 
problems. On the one hand, the function of the protein is restored without needing to introduce the complete gene in a vector. On the other hand, some preclinical trials have restored dystrophin levels significantly in all 
the affected muscles. For these reasons, the therapy proposed in the present review supposes an encouraging approach to an effective treatment of the disease. However, there is still needed a more accurate technique 
with the final goal of offering to the patient a personal therapy in order to improve his life quality.  
   REFERENCES 
3. Walmsley GL,et al. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient 
cavalier king charles spaniels is amenable to exon 51 skipping. PLoS One. 2010 Jan 13;5(1):e8647. 
 
4. Cirak S,et al. Exon skipping and dystrophin   restoration in patients with Duchenne muscular 
dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 
2, dose-escalation study. Lancet. 2011 Aug 13;378(9791):595-605.  
1. Sugita H, Takeda S. Progress in muscular dystrophy research with special emphasis on gene therapy. 
Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(7):748-56.  
 
2. Nakamura A, Takeda S. Mammalian models of Duchenne Muscular Dystrophy: pathological 
characteristics and therapeutic applications. J Biomed Biotechnol. 2011;2011:184393.  
 
   OBJECTIVES 
The aim of the present review is to explain what are the causes of the disease and their 
consequences, specially in a molecular level. We focus the attention on the description of one of the 
most important treatments which is currently being tested, exon-skipping of the altered exons of the 
dystrohin gene.  
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